Trexquant Investment LP Has $1.51 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

Key Points

• Trexquant Investment LP significantly increased its stake in Vera Therapeutics, boosting ownership by 187.1%, acquiring an additional 40,913 shares during the first quarter.
• Vera Therapeutics has received favorable analyst ratings, with a consensus of "Moderate Buy" and an average price target of $63.00.
• Vera Therapeutics reported earnings of ($1.20) per share, missing estimates, and anticipates posting -2.89 EPS for the current year.

Trexquant Investment LP raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 187.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,777 shares of the company's stock after acquiring an additional 40,913 shares during the period. Trexquant Investment LP owned about 0.10% of Vera Therapeutics worth $1,508,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in VERA. Hsbc Holdings PLC acquired a new position in Vera Therapeutics in the 4th quarter valued at approximately $264,000. Northern Trust Corp raised its holdings in Vera Therapeutics by 24.6% in the 4th quarter. Northern Trust Corp now owns 455,007 shares of the company's stock valued at $19,242,000 after acquiring an additional 89,707 shares in the last quarter. Algert Global LLC raised its holdings in Vera Therapeutics by 66.4% in the 4th quarter. Algert Global LLC now owns 38,550 shares of the company's stock valued at $1,630,000 after acquiring an additional 15,386 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Vera Therapeutics by 31.7% in the 4th quarter. Ameriprise Financial Inc. now owns 30,021 shares of the company's stock valued at $1,270,000 after acquiring an additional 7,227 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in Vera Therapeutics in the 4th quarter valued at approximately $1,031,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on VERA. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $85.00 price objective (up from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $63.00.

Insider Buying and Selling

In other Vera Therapeutics news, Director Patrick G. Enright purchased 40,607 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were acquired at an average cost of $22.35 per share, for a total transaction of $907,566.45. Following the transaction, the director directly owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. The trade was a 1.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 16.30% of the stock is currently owned by company insiders.

Vera Therapeutics Price Performance

NASDAQ VERA traded down $0.94 during trading hours on Wednesday, reaching $24.14. 1,341,794 shares of the company's stock were exchanged, compared to its average volume of 1,371,497. The stock has a market cap of $1.54 billion, a PE ratio of -6.74 and a beta of 1.17. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $51.61. The firm has a fifty day moving average of $22.25 and a 200-day moving average of $23.29. The company has a current ratio of 17.03, a quick ratio of 17.03 and a debt-to-equity ratio of 0.16.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period last year, the company posted ($0.62) earnings per share. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.